WashingtonExec
  • News & Headlines
  • Executive Councils
  • Videos
  • Podcast
  • Events
    • 🏆 Pinnacle Awards
    • 🏆 Chief Officer Awards
  • About
  • Contact Us
Latest Video:
https://www.youtube.com/watch?v=3_0OGr8ie5g&list=UULFQpADaPZpDb8HwwScpJ2OPQ
Podcast Episodes
LinkedIn Facebook Twitter Instagram YouTube
LinkedIn Facebook Twitter Instagram YouTube
WashingtonExec
Subscribe To The Daily
  • News & Headlines
  • Executive Councils
  • Videos
  • Podcast
  • Events
    • 🏆 Pinnacle Awards
    • 🏆 Chief Officer Awards
  • About
  • Contact Us
LinkedIn YouTube Twitter
WashingtonExec
You are at:Home»News»Contract Awards»Dovel Technologies Secures 2 Biologics Surveillance IDIQs from FDA
Contract Awards

Dovel Technologies Secures 2 Biologics Surveillance IDIQs from FDA

By WashingtonExec Staff WriterNovember 5, 2018
Share
LinkedIn Facebook Twitter Email
Damon Griggs, Dovel Technologies
Damon Griggs, Dovel Technologies

Dovel Technologies has won two contracts from the Food and Drug Administration’s Center for Biologics Effectiveness and Research to help build an ecosystem of tools to support biologic product safety.

Dovel has been awarded under two separate 5-year indefinite-delivery, indefinite-quantity deals: one for data, tools and infrastructure for surveillance of biologics and one covering the development of new and innovative methods for automated reporting for CBER-regulated biological products.

Dovel secured one of four awards for each of the IDIQs. Each award has a ceiling of $75 million.

“We are excited to get to work helping build the data strategy and tools that will enhance CBER’s efficiency in meeting their mission to assure the safety and efficacy of biologic products,” said Damon Griggs, Dovel president and chief operating officer. “Our team has exciting and innovative approaches and solutions for data science and automation using machine learning, natural language processing, and more to meet the needs of CBER.”

The center’s Biologics Effectiveness and Safety, or BEST, initiative aims to expand and enhance current capabilities with respect to data sources, infrastructure, methods and tools and to conduct active surveillance, epidemiologic studies and automated reporting to improve the the safety and efficacy of biologic products including vaccines, blood and blood products, tissues, and advanced therapeutics.

Related: Dovel Technologies to Update Federal Grants Management System

Previous ArticleRigil Corp. Picks Up $33.5M FAA Deal
Next Article Top AI Execs to Watch: Balan Ayyar, Percipient.ai

Related Posts

Top Space Execs to Watch in 2023: Lockheed Martin Space’s Stacy Kubicek

Top Space Execs to Watch in 2023: Airbus U.S. Space & Defense’s Debra Facktor

Top Space Execs to Watch in 2023: ASRC Federal’s Scott Altman

Comments are closed.

Chief Officer Awards Winners Revealed - Click to view the winners
Trending

Top Space Execs to Watch in 2023: Lockheed Martin Space’s Stacy Kubicek

May 30, 2023

Top Space Execs to Watch in 2023: Airbus U.S. Space & Defense’s Debra Facktor

May 30, 2023

Top Space Execs to Watch in 2023: ASRC Federal’s Scott Altman

May 30, 2023

Top Space Execs to Watch in 2023: LMI’s Zac Gorrell

May 30, 2023

Top Space Execs to Watch in 2023: SAIC’s David Ray

May 29, 2023
Quick Links
  • Executive Councils & Committees
  • Chief Officer Awards
  • Pinnacle Awards
  • K-12 STEM Symposium
  • Advertise With Us
  • About WashingtonExec
  • Contact

Subscribe to The Daily

Get federal business news & insights delivered to your inbox.

  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
Copyright 2023 © WashingtonExec, Inc. | All Rights Reserved. Powered by J Media Group

Type above and press Enter to search. Press Esc to cancel.